Get the Stockscreener App
4.76
2.46%
-0.12
Taysha Gene Therapies Inc stock is traded at $4.76, with a volume of 18.09M.
It is down -2.46% in the last 24 hours and up +64.14% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.88
Open:
$5.05
24h Volume:
18.09M
Relative Volume:
3.37
Market Cap:
$1.30B
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-14.00
EPS:
-0.34
Net Cash Flow:
$-82.52M
1W Performance:
+46.46%
1M Performance:
+64.14%
6M Performance:
+277.78%
1Y Performance:
+135.64%
1-Day Range:
$4.485
$5.40
1-Week Range:
$3.10
$5.40
52-Week Range:
$1.05
$5.40
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.76 | 1.33B | 8.10M | -92.72M | -82.52M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Taysha Gene Therapies stock hits 52-week high at 5.05 USD - Investing.com Nigeria
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
US FDA Backing Is A Breakthrough For Taysha’s Gene Therapy - insights.citeline.com
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy | FinancialCont - FinancialContent
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals - Stocktwits
Could Taysha's FDA Alignment Fast-Track Its BLA Submission? - RTTNews
Will Taysha Gene Therapies Inc. stock maintain growth storyWeekly Trade Summary & AI Enhanced Trade Execution Alerts - newser.com
Analyzing drawdowns of Taysha Gene Therapies Inc. with statistical toolsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
Can Taysha Gene Therapies Inc. stock hit record highs againInsider Buying & Daily Stock Trend Watchlist - newser.com
Visual analytics tools that track Taysha Gene Therapies Inc. performanceDividend Hike & Growth Oriented Trading Recommendations - newser.com
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy | Conservative - FinancialContent
Taysha Gene Therapies Inc. (TSHA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Taysha Gene Therapies Announces FDA Breakthrough Therapy - GlobeNewswire
Taysha Gene Therapies (TSHA) Stock Soars 52% After FDA Grants Breakthrough Therapy Designation for Rett Syndrome - parameter.io
Taysha Gene Therapies: Shares Are Soaring On FDA Alignment, But Caution Is Advised - Seeking Alpha
Todays Analyst Rating for TSHA: Baird Raises Price Target | TSHA Stock News - GuruFocus
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - TipRanks
Baird raises Taysha Gene Therapies stock price target to $12 on Rett syndrome study - Investing.com
Promising Prospects for Taysha Gene Therapies: Buy Rating Backed by Strategic Advancements and Regulatory Endorsements - TipRanks
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Did TSHA Stock Surge Today: FDA Breakthrough Therapy Designation - Tokenist
Taysha Gene Therapies (TSHA) Sees Target Price Boost on FDA Appr - GuruFocus
Needham Ups Price Target for TSHA Amidst Continued 'Buy' Rating - GuruFocus
Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy - Stocktwits
Taysha Gene Therapies price target raised to $10 from $8 at Needham - TipRanks
Taysha may file for approval sooner than expected; Metagenomi ends work with Affini-T - Endpoints News
Taysha Gene Therapies (TSHA) Surges on FDA Breakthrough Designat - GuruFocus
Taysha wins FDA breakthrough tag for lead drug (TSHA:NASDAQ) - Seeking Alpha
Taysha Gene Therapies Shares Surge After FDA Grants Breakthrough Therapy Status - MSN
TSHA Stock Soars: Talent and Strategy Drive Momentum - StocksToTrade
Taysha Gene Therapies: New Employment Boost - timothysykes.com
Taysha Gets Breakthrough-Therapy Designation for Investigational Treatment - MarketScreener
Taysha Gene Therapies stock soars after FDA breakthrough therapy designation - Investing.com
Taysha Gene Therapies (TSHA) Advances with FDA Breakthrough Designation for Rett Syndrome - GuruFocus
Taysha Gene Therapies Gains FDA Breakthrough Designation - TipRanks
FDA grants breakthrough therapy designation to Taysha’s Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies announces FDA BTD to TSHA-102 - TipRanks
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - The Manila Times
100% Response Rate: Taysha's Gene Therapy Breakthrough Could Transform Rett Syndrome Treatment - Stock Titan
Will Taysha Gene Therapies Inc. stock continue dividend increasesPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
How to interpret RSI for Taysha Gene Therapies Inc. stockMarket Activity Report & Consistent Profit Trading Strategies - newser.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.5%Time to Sell? - MarketBeat
Is Taysha Gene Therapies Inc. trending in predictive chart modelsWeekly Trade Summary & Weekly Stock Performance Updates - newser.com
What analysts say about Taysha Gene Therapies Inc stockDouble Top/Bottom Patterns & Turn Data into Profits With Our Strategies - earlytimes.in
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.68%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):